• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

    5/8/25 8:00:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLN alert in real time by email

    Company further extends cash guidance into 2028

    Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2025, and reviewed recent business highlights.

    "Silence delivered another strong quarter focused on clinical and operational execution," said Craig Tooman, President and Chief Executive Officer at Silence. "We remain focused on advancing enrollment into the SANRECO Phase 2 study of divesiran, a first-in-class siRNA program in PV, and continue to be on-track to complete enrollment by the end of this year. We are also looking forward to sharing additional results from the Phase 1 portion of the SANRECO study during an oral presentation at EHA next month."

    Rhonda Hellums, Chief Financial Officer at Silence, added, "We ended the first quarter with over $136 million in cash, cash equivalents, and short-term investments. To maintain a healthy financial position while prioritizing the advancement of our core PV program, we are implementing cost savings initiatives and further extending our cash guidance into 2028. We remain committed to realizing the vast potential of our proprietary mRNAi GOLD™ platform and will continue to invest prudently in areas where we see the greatest opportunity to enhance value to Silence stakeholders."

    First Quarter 2025 & Recent Business Highlights

    Divesiran for Polycythemia Vera (PV)

    • Additional Phase 1 results from the SANRECO study of divesiran in PV patients have been accepted for oral presentation during the European Hematology Association (EHA) 2025 Annual Congress being held in Milan, Italy from June 12 – 15, 2025.
    • Advanced patient enrollment into the Phase 2 portion of the SANRECO study of divesiran in PV patients and remain on-track to complete enrollment by year-end 2025.

    Zerlasiran for Cardiovascular Disease

    • Advanced core Phase 3 readiness activities, including manufacturing and supply scale up, which remain on-track to complete by mid-2025. Partnering discussions for potential Phase 3 development are ongoing.

    Collaborations

    • A Phase 1 study of SLN312 (licensed to AstraZeneca) is ongoing.

    Corporate Updates

    • Appointed Tim McInerney to the Company's Board of Directors, effective May 5, 2025. Mr. McInerney is a seasoned executive and board member with over 30 years of experience in both the investment and pharmaceutical industries.

    First Quarter 2025 Financial Highlights

    • Cash Position: Cash and cash equivalents, and short-term investments of $136.5 million as of March 31, 2025, compared with $147.3 million as of December 31, 2024.
    • R&D Expenses: Research and development (R&D) expenses were $20.8 million, an increase of $9.0 million compared to the first quarter of 2024. The increase was primarily due to the advancement of our clinical trials and an increase in manufacturing activities for our proprietary programs.
    • G&A Expenses: General and administrative (G&A) expenses were $7.7 million, an increase of $1.0 million compared to the first quarter of 2024. The increase is primarily due to the cost of additional reporting and compliance requirements in connection with our transition to becoming a domestic issuer and large accelerated filer.
    • Net Loss: Net loss was $28.5 million, or $0.20 basic and diluted net loss per share, compared to a net loss of $2.3 million, or $0.02 basic and diluted net loss per share for the first quarter of 2024.
    • Total ADSs outstanding were approximately 47,230,283 as of March 31, 2025.

    Updates to 2025 Financial Guidance

    • Silence has implemented cost savings initiatives to strengthen its financial position and further extend its cash runway into 2028. These measures include general and administrative reductions, as well as further prioritizing early-stage research projects and resources. The Company remains committed to realizing the vast potential of its proprietary mRNAi GOLD™ platform and will continue to invest prudently in key areas focused on enhancing value to Silence stakeholders.

    About Silence Therapeutics

    Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company's business strategy and plans, including the Company's clinical development activities and timelines; the progression and advancement of collaborations; the expected benefits of the Company's cost saving initiatives; the Company's ability to enhance stakeholder value; and the Company's anticipated extended cash runway. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company's history of net operating losses; the company's ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company's product candidates; the company's ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company's product candidates; the company's reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company's ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled "Risk Factors" contained in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company's other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Silence Therapeutics plc

    Condensed Consolidated Balance Sheets

    (Unaudited, in thousands, except share and per share data)

     

     

    Period ended

     

    March 31, 2025

     

    December 31, 2024

    Current assets

     

     

     

     

     

    Cash and cash equivalents

    $

    64,886

     

     

    $

    121,330

     

    Short-term investments

     

    71,648

     

     

     

    26,004

     

    R&D benefit receivable

     

    16,796

     

     

     

    24,396

     

    Other current assets

     

    16,419

     

     

     

    14,664

     

    Trade receivables

     

    41

     

     

     

    972

     

    Total current assets

     

    169,790

     

     

     

    187,366

     

    Property, plant and equipment

     

    1,693

     

     

     

    1,818

     

    Operating lease right-of-use assets

     

    107

     

     

     

    157

     

    Goodwill

     

    9,784

     

     

     

    9,392

     

    Other intangible assets

     

    310

     

     

     

    312

     

    Other long-term assets

     

    3,614

     

     

     

    3,590

     

    Total assets

    $

    185,298

     

     

    $

    202,635

     

     

     

     

     

     

     

    Current liabilities

     

     

     

     

     

    Contract liabilities

    $

    (392

    )

     

    $

    (306

    )

    Trade and other payables

     

    (18,812

    )

     

     

    (16,399

    )

    Operating lease liabilities, current

     

    (60

    )

     

     

    (117

    )

    Total current liabilities

     

    (19,264

    )

     

     

    (16,822

    )

    Contract liabilities

     

    (53,291

    )

     

     

    (51,790

    )

    Total liabilities

    $

    (72,555

    )

     

    $

    (68,612

    )

    Commitments and contingencies (Note 20)

     

     

     

     

     

     

     

     

     

     

     

    Shareholders' equity

     

     

     

     

     

    Ordinary shares - par value £0.05 per share; 141,690,850 shares

    issued at March 31, 2025 (December 31, 2024: 141,674,074)

     

    (10,289

    )

     

     

    (10,288

    )

    Additional paid-in capital

     

    (613,074

    )

     

     

    (609,560

    )

    Accumulated deficit

     

    502,536

     

     

     

    474,044

     

    Accumulated other comprehensive loss

     

    8,084

     

     

     

    11,781

     

    Total shareholders' equity

     

    (112,743

    )

     

     

    (134,023

    )

     

     

     

     

     

     

    Total liabilities and shareholders' equity

    $

    (185,298

    )

     

    $

    (202,635

    )

    Silence Therapeutics plc

    Condensed Consolidated Statements of Operations and Comprehensive Loss

    (Unaudited, in thousands, except share and per share data)

     

     

    Three months ended March 31,

     

    2025

     

    2024

    Revenue

    $

    142

     

     

    $

    15,699

     

    Cost of sales

     

    (54

    )

     

     

    (2,800

    )

    Gross profit

     

    88

     

     

     

    12,899

     

    Research and development costs

     

    (20,813

    )

     

     

    (11,845

    )

    General and administrative expenses

     

    (7,684

    )

     

     

    (6,635

    )

    Operating loss

     

    (28,409

    )

     

     

    (5,581

    )

    Foreign currency (loss)/gain, net

     

    (3,769

    )

     

     

    351

     

    Other income, net

     

    969

     

     

     

    667

     

    Benefit from R&D credit

     

    2,679

     

     

     

    2,495

     

    Loss before income tax expense

     

    (28,530

    )

     

     

    (2,068

    )

    Income tax expense

     

    —

     

     

     

    (244

    )

    Net Loss

    $

    (28,530

    )

     

    $

    (2,312

    )

    Loss per share (basic and diluted)

    $

    (0.20

    )

     

    $

    (0.02

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250508742900/en/

    Inquiries:

    Silence Therapeutics plc

    Gem Hopkins, VP, IR and Corporate Communications

    [email protected]

    Tel: +1 (646) 637-3208

    Get the next $SLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLN

    DatePrice TargetRatingAnalyst
    2/11/2025$6.00Sell
    Goldman
    12/2/2024Outperform
    BMO Capital Markets
    9/3/2024$40.00Buy
    Jefferies
    1/31/2024$67.00Outperform
    BMO Capital Markets
    5/8/2023$20.00Overweight
    Morgan Stanley
    12/9/2022$18.00Equal-Weight
    Morgan Stanley
    3/31/2022$33.00Buy
    Chardan Capital Markets
    More analyst ratings

    $SLN
    Leadership Updates

    Live Leadership Updates

    See more
    • Silence Therapeutics Welcomes Tim McInerney to Board of Directors

      Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

      5/6/25 7:45:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

      Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence's Board of Directors (the "Board") since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence's Chairman of the Board, commented, "Alistair has made significant contributions to the Board and the Company over the past nine years. During his time on the Board, the Company has transitioned into a global player focused on the developmen

      4/29/24 8:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

      Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&D at Silence, to ensure an efficient and smooth transition for Dr. Campion's retirement by year-end. Dr. Romano has served as non-execut

      3/28/23 7:05:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Company further extends cash guidance into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2025, and reviewed recent business highlights. "Silence delivered another strong quarter focused on clinical and operational execution," said Craig Tooman, President and Chief Executive Officer at Silence. "We remain focused on advancing enrollment into the SANRECO Phase 2 study of divesiran, a first-in-class siRNA program in PV, and continue to be on-track to complete enrollment by the end of this year. We are a

      5/8/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Welcomes Tim McInerney to Board of Directors

      Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

      5/6/25 7:45:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

      Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineer

      3/5/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Financials

    Live finance-specific insights

    See more
    • Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

      The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. "2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD™ platform to silence disease causing genes," said Craig Tooman, President and CEO of Silence. "In 2025, we are prioritizing investment in programs targeting rare conditi

      2/27/25 7:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

      Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company's website. Deta

      2/13/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

      Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc ("Silence" or the "Company"), (NASDAQ:SLN), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran (SLN124), a siRNA (short interfering RNA) targeting TMPRSS6, in patients with polycythemia vera (PV). "With today's very exciting PV da

      6/27/24 7:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    SEC Filings

    See more

    $SLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 10-Q filed by Silence Therapeutics Plc

      10-Q - Silence Therapeutics plc (0001479615) (Filer)

      5/8/25 8:35:12 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Plc filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Silence Therapeutics plc (0001479615) (Filer)

      5/8/25 8:10:25 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Silence Therapeutics Plc

      PRE 14A - Silence Therapeutics plc (0001479615) (Filer)

      5/6/25 8:06:29 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/14/24 1:13:14 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/14/24 9:44:01 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/12/24 4:31:49 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Silence Therapeutics with a new price target

      Goldman initiated coverage of Silence Therapeutics with a rating of Sell and set a new price target of $6.00

      2/11/25 7:12:20 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets reiterated coverage on Silence Therapeutics

      BMO Capital Markets reiterated coverage of Silence Therapeutics with a rating of Outperform

      12/2/24 10:09:42 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Silence Therapeutics with a new price target

      Jefferies initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $40.00

      9/3/24 8:14:09 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Large owner Griffiths Richard Ian

      4 - Silence Therapeutics plc (0001479615) (Issuer)

      5/8/25 7:08:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Large owner Griffiths Richard Ian

      4 - Silence Therapeutics plc (0001479615) (Issuer)

      5/2/25 10:28:34 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Large owner Griffiths Richard Ian

      4 - Silence Therapeutics plc (0001479615) (Issuer)

      4/30/25 7:13:20 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care